A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.

@article{Lorenzo2010ALR,
  title={A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.},
  author={Gabriele Di Lorenzo and Margareth Imbimbo and Davide Leopardo and Rudy Marciano and P Federico and Carlo Buonerba and Barbara Salvatore and Alfredo Marinelli and Giampiero Palmieri},
  journal={International journal of immunopathology and pharmacology},
  year={2010},
  volume={23 3},
  pages={
          951-4
        }
}
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. No effective systemic treatment has been established, except for sorafenib chemotherapy. In fact, sorafenib has proved to provide a statistically significant survival extension of about two months in two phase III trials in the North America-Europe area and in the Asia-Pacific area, which respectively reported a median survival after treatment of 10.7 and 6.5 months, respectively. We report the case… CONTINUE READING
BETA